Skinbiotherapeutics Plc Stock Fundamentals
| SBTX Stock | 15.88 0.37 2.28% |
SkinBioTherapeutics PLC fundamentals help investors to digest information that contributes to SkinBioTherapeutics' financial success or failures. It also enables traders to predict the movement of SkinBioTherapeutics Stock. The fundamental analysis module provides a way to measure SkinBioTherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SkinBioTherapeutics stock.
At this time, SkinBioTherapeutics' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 2.5 M in 2024, despite the fact that Operating Income is likely to grow to (2.6 M). SkinBioTherapeutics | Select Account or Indicator |
SkinBioTherapeutics PLC Company Return On Equity Analysis
SkinBioTherapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current SkinBioTherapeutics Return On Equity | -1.19 |
Most of SkinBioTherapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SkinBioTherapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
SkinBioTherapeutics Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, SkinBioTherapeutics PLC has a Return On Equity of -1.1864. This is much lower than that of the Personal Care Products sector and significantly lower than that of the Consumer Staples industry. The return on equity for all United Kingdom stocks is notably higher than that of the company.
SkinBioTherapeutics PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SkinBioTherapeutics's current stock value. Our valuation model uses many indicators to compare SkinBioTherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SkinBioTherapeutics competition to find correlations between indicators driving SkinBioTherapeutics's intrinsic value. More Info.SkinBioTherapeutics PLC is rated second in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SkinBioTherapeutics' earnings, one of the primary drivers of an investment's value.SkinBioTherapeutics Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SkinBioTherapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SkinBioTherapeutics could also be used in its relative valuation, which is a method of valuing SkinBioTherapeutics by comparing valuation metrics of similar companies.SkinBioTherapeutics is currently under evaluation in return on equity category among its peers.
SkinBioTherapeutics Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (13.01) % | ||||
| Current Valuation | 34.38 M | ||||
| Shares Outstanding | 228.44 M | ||||
| Shares Owned By Insiders | 19.32 % | ||||
| Shares Owned By Institutions | 16.45 % | ||||
| Price To Book | 10.17 X | ||||
| Price To Sales | 224.34 X | ||||
| Revenue | 132.06 K | ||||
| Gross Profit | 45.34 K | ||||
| EBITDA | (2.96 M) | ||||
| Net Income | (2.84 M) | ||||
| Total Debt | 100.65 K | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (2.65 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 56.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 36.26 M | ||||
| Total Asset | 2.59 M | ||||
| Retained Earnings | (11.12 M) | ||||
| Working Capital | 1.19 M | ||||
| Net Asset | 2.59 M |
About SkinBioTherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SkinBioTherapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SkinBioTherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SkinBioTherapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 36.6 K | 38.4 K | |
| Total Revenue | 151.9 K | 159.5 K | |
| Cost Of Revenue | 53.9 K | 56.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SkinBioTherapeutics Stock Analysis
When running SkinBioTherapeutics' price analysis, check to measure SkinBioTherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SkinBioTherapeutics is operating at the current time. Most of SkinBioTherapeutics' value examination focuses on studying past and present price action to predict the probability of SkinBioTherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SkinBioTherapeutics' price. Additionally, you may evaluate how the addition of SkinBioTherapeutics to your portfolios can decrease your overall portfolio volatility.